Drug intelligence / Profile preview

99mtc-radiolabelled tiotropium

Development stage: Unknown
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Inhalation

Overview

99mTc-radiolabelled tiotropium is a radiolabelled version of tiotropium used for research and diagnostic purposes to study lung deposition patterns. Tiotropium itself is a long-acting muscarinic antagonist (LAMA) bronchodilator that works by blocking M1, M2, and M3 muscarinic acetylcholine receptors in the lungs, preventing acetylcholine binding. This action leads to bronchodilation, decreased mucous gland secretions, and reduced airway inflammation. The radiolabelled version allows researchers to track the distribution and deposition of the drug in the lungs using gamma scintigraphy.

Other names: radiolabeled tiotropium

Targets

M1 (Muscarinic acetylcholine receptor M1)CHRM2 (M2)CHRM3 (M3)

Beyond the preview

Go deeper on 99mtc-radiolabelled tiotropium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 99mtc-radiolabelled tiotropium.

Explore the full profile